<DOC>
	<DOCNO>NCT02689167</DOCNO>
	<brief_summary>Patients candidate first line treatment Sunitinib 50mg 4/6 regimen accordance Marketing Authorisation meet inclusion/exclusion criterion offer participation study consultation part usual care . The patient include Sunitinib treatment start . Thereafter , sunitinib initiate 50 mg/day ; regimen 4/6 ( Marketing Authorisation Indication ) , 4 week `` `` alternate 2 week `` `` As soon dose schedule adjustment require , regardless cause , patient randomise 1/1 : - Either arm A receive 37.5mg Sunitinib per day 4/6 regimen ( accordance Marketing Authorisation ) ; 4 week `` `` alternate 2 week `` `` - Or arm B receive 50mg Sunitinib per day 2/3 regimen ( investigational arm ) ; 2 week `` `` alternate 1 week `` ``</brief_summary>
	<brief_title>Study Assess Various Sunitinib Schedules Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Key Men woman 18 year old Patients local , advance inoperable metastatic ( MRCC ) renal cell carcinoma start first line treatment Sunitinib 50mg ( 4/6 regimen ) accord Marketing Authorisation Indication Patients histologically cytologically confirm renal cancer , clear cell variant clear cell component Karnofsky performance status ≥ 70 % Adequate organ function : Absolute neutrophil ( N ) count ≥ 1 500 / µL Platelets ≥ 100 000 / µL Haemoglobin ≥ 10 g/dL Adjusted serum calcium ≤ 2.6 mmol/L Creatinine clearance ≥ 30 mL/min ( MDRD formula ) Total bilirubin ≤ 1.5 x ULN ( upper limit normal range ) AST ≤ 2.5 x ULN ALT ≤ 2.5 x ULN OR AST ALT ≤ 5 x ULN liver abnormality due liver metastases AST = aspartate aminotransferase ALT = alanine aminotransferase Key Renal carcinoma clear cell component . Previous systemic treatment RCC regardless type ( include target therapy , immunotherapy , chemotherapy , hormone experimental therapy ) . Previous concomitant treatment bisphosphonate denosumab allow . Patients whose clinical state comorbidities consistent administration Sunitinib initial dose 50mg/day 4 week 6 . Grade 3 haemorrhage within 4 week start treatment Sunitinib ( accord NCICTCAE toxicity score version 3.0 ) . The presence past history cancer 3 year inclusion study Major surgery within 4 week sunitinib initiation Past history symptomatic cerebral metastasis , spinal cord compression meningeal carcinomatosis . Patients cerebral metastasis discover incidentally image asymptomatic excluded metastasis treat ( radiotherapy and/or surgery ) period least 4 week end treatment inclusion study clinical radiological sign relapse , corticosteroid dose exceed 10mg/day prednisone equivalent . Subjects exclude subject sign grade ≥ 2 treatmentrelated complication . Any following feature within 6 month administration Sunitinib : myocardial infarction , severe/unstable angina , coronary artery/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack . Pulmonary embolism deep vein thrombosis within 3 month inclusion ( unless 's stable , asymptomatic treat low molecular weight heparin least 6 week inclusion ) . Any known acute chronic disorder ( severe chronic obstructive pulmonary disease ) opinion investigator could impact patient 's capacity receive study treatment make interpretation toxicity adverse event difficult . Known HIV infection . History chronic active hepatitis include subject carrier hepatitis B ( HBV ) hepatitis C ( HCV ) virus . Existence uncontrolled infection . Uncontrolled hypertension define blood pressure &gt; 150 mmHg systolic &gt; 100 mmHg diastolic despite optimal antihypertensive therapy ( blood pressure must control inclusion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>sunitinib</keyword>
	<keyword>metastatic</keyword>
	<keyword>schedule</keyword>
	<keyword>toxicity</keyword>
	<keyword>safety</keyword>
</DOC>